Colorado board decides Novartis arthritis drug is unaffordable

Taking stock of the drug industry, from the lab to the medicine chest

June 14, 2024 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Adobe STAT+ | Colorado board decides a pricey Novartis medicine is unaffordable "We hope they set an upper payment limit to reduce the financial weight that high-cost drugs have," Colorado Consumer Health Initiative said. By Ed Silverman STAT+ | Up and down the ladder: The latest comings and goings From new hires to departures, promotions and transfers, here are the latest comings and goings in the pharmaceutical industry. By Ed Silverman Opinion: Telling new stories can help people see the value of vaccines Improving vaccination rates in the U.S. requires innovative approaches to reclaiming and reframing the public conversation about vaccines. By Julie Sweetland NIH Opinion: NIH needs reform and restructuring, key Republican committee chairs say House committee chairs propose turning 27 NIH institutes and centers into 15 new ones, urge move away from a disease-specific silo approach. By Cathy McMorris Rodgers and Robert B. Aderholt

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2024, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser